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Abstract
Chikungunya virus (CHIKV) is a mosquito-borne virus that causes a febrile syndrome in
humans associated with acute and chronic debilitating joint and muscle pain. Currently no
licensed vaccines or therapeutics are available to prevent or treat CHIKV infections. We
recently isolated a panel of potently neutralizing human monoclonal antibodies (mAbs), one
(4N12) of which exhibited prophylactic and post-exposure therapeutic activity against
CHIKV in immunocompromised mice. Here, we describe the development of an engineered
CHIKV mAb, designated SVIR001, that has similar antigen binding and neutralization pro-
files to its parent, 4N12. Because therapeutic administration of SVIR001 in immunocompe-
tent mice significantly reduced viral load in joint tissues, we evaluated its efficacy in a rhesus
macaque model of CHIKV infection. Rhesus macaques that were treated after infection with
SVIR001 showed rapid elimination of viremia and less severe joint infiltration and disease
compared to animals treated with SVIR002, an isotype control mAb. SVIR001 reduced viral
burden at the site of infection and at distant sites and also diminished the numbers of acti-
vated innate immune cells and levels of pro-inflammatory cytokines and chemokines.
SVIR001 therapy; however, did not substantively reduce the induction of CHIKV-specific B
or T cell responses. Collectively, these results show promising therapeutic activity of a
human anti-CHIKV mAb in rhesus macaques and provide proof-of-principle for its possible
use in humans to treat active CHIKV infections.
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Author summary
Chikungunya virus (CHIKV) causes fever, rash, and acute and chronic arthralgia. Cur-
rently there are no approved therapies to treat or vaccines to prevent CHIKV infection in
humans. In this study, we engineered SVIR001, a recombinant fully human monoclonal
antibody (mAb) that eliminated viremia, reduced viral load at the site of infection, and
diminished spread to distant target tissues in rhesus macaques when administered after
infection. SVIR001 treatment reduced joint inflammation and disease without impairing
the induction of the adaptive immune response. These results demonstrate the efficacy of
mAb therapy to reduce the severity of CHIKV disease.
Introduction
Chikungunya virus (CHIKV) is a mosquito-transmitted, positive-sense, enveloped RNA virus.
The mature virion has an icosahedral surface studded with viral glycoproteins E1 and E2 and a
central capsid core, which encapsulates viral RNA [1]. CHIKV causes severe, debilitating joint
and musculoskeletal disease that may persist for months to years following acute infection [2–
4]. Over the past decade, CHIKV has caused several large-scale epidemics and expanded its geo-
graphic range to five continents. During the 2004–2007 Indian Ocean Island outbreak, CHIKV
emerged from Kenya to several islands in the Indian Ocean, where infection attack rates
reached as high as 75% of the population [5–7], and to India, where a suspected 1.3 million peo-
ple were infected during 2006 [8]. From India, the virus spread to China and Southeast Asia [9].
At the end of 2013, local transmission of CHIKV occurred in the Caribbean island of Saint Mar-
tin [10]. CHIKV disseminated rapidly throughout the Caribbean and to neighboring countries
in Central and South America, infecting an estimated 1.8 million people in more than 40 coun-
tries [11]. The recent outbreak of CHIKV in the Americas raises concern about its continued
spread in this region and its introduction into new areas with large naïve populations.
In humans, CHIKV infection symptoms appear within 3 to 12 days after the bite of an
infected mosquito [12]. During the acute phase, humans experience arthralgias, high-grade
fever, skin rash, and headaches. CHIKV-induced polyarthralgia can be debilitating, affecting
many peripheral joints including the ankles, knees, wrists, and fingers [13]. The elderly (>60
years) and newborns typically sustain higher viral loads [14] and are at increased risk for severe
disease manifestations such as encephalitis, seizures, cardiovascular complications, and death
[15, 16]. During the convalescent phase of the disease, viremia, fever and rash resolve although
joint and muscle pain may linger for months to years [3, 17]. Continued long-term arthralgias
is a common symptom, with one population-based survey reporting that 43–75% of patients
experienced long-term joint pain for at least two years following CHIKV infection [18].
Although infectious virus has not been recovered from joints of patients experiencing chronic
pain, CHIKV RNA and antigen were detected in muscle and synovial biopsies months after the
resolution of the acute symptoms [3, 19]. These results suggest that CHIKV may establish a per-
sistent infection in musculoskeletal tissue, which results in chronic joint and muscle pain. Cur-
rently there are no approved vaccines or therapies for the prevention or treatment of CHIKV.
Many of the candidate CHIKV vaccines under development rely on the induction of neu-
tralizing antibodies for protection against challenge [20–22]. In humans, prior infection and
development of anti-CHIKV neutralizing antibodies have been associated with protection
from reinfection, further supporting the development of antibody-based vaccines and thera-
peutics [23–25]. CHIKV-specific IgM can be detected by day 4 of illness and CHIKV-specific
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IgG antibodies can be detected by day 10 [25, 26]. The antibody response following CHIKV
infection is directed primarily against viral glycoprotein E2 and is long-lived [27]. Anti-
CHIKV antibodies generated following CHIKV infection possess broad neutralizing activity
against viruses belonging to different CHIKV genotypes [27, 28], and antibodies generated fol-
lowing infection with closely related non-CHIKV Alphaviruses could have cross-neutralizing
activity against CHIKV [29]. Since CHIKV naturally infects nonhuman primates (NHPs) dur-
ing sylvatic transmission cycles, NHPs are a relevant animal model for testing CHIKV vaccines
and therapeutics and studying immunity. NHPs also develop antibodies directed against
CHIKV following infection; mapping of the linear B cell epitopes showed that these antibodies
were directed against several CHIKV proteins, including E2 [26, 30].
Antibody-mediated protection against CHIKV infection has been reported in animal mod-
els. Passive transfer of immune sera into susceptible neonatal mice as well as Ifnar-/- and
AG129 mice protects against lethal CHIKV challenge [31–34]. Mice deficient in B cells (μMT)
develop a nonlethal infection with persistent viremia [35, 36], which can be prevented by pas-
sive transfer of serum-derived anti-CHIKV polyclonal antibodies [37]. Neutralizing mouse
monoclonal antibodies (mAbs) have protective efficacy in animal models when administered
as post-exposure therapy [31, 32]. Our group previously established the utility of mAb therapy
for CHIKV in Ifnar-/- mice and in rhesus macaques (Macaca mulatta) [32, 38]. In Ifnar-/-
mice, passive transfer of a combination of two mouse mAbs (CHK-152 and CHK-166) against
E2 and E1 proteins increased survival when given up to 60 hours post-infection. In rhesus
macaques, CHK-152 and CHK-166 combination therapy at days 1 and 3 of CHIKV infection
resulted in elimination of viremia and reduction of viral spread to joints and muscles of the
legs. However, the viral load at the site of infection and in the draining lymph nodes were
unchanged relative to controls at 7 days post infection (dpi). These results suggested that a
CHIKV mAb therapeutic required further optimization to control acute infection, minimize
viral persistence, and prevent long-term joint disease.
To this end, we recently isolated 4N12, a highly neutralizing human mAb, from a subject
who had a history of CHIKV infection 5.5 years prior to blood donation [28]. This mAb exhib-
ited high levels of protection in Ifnar-/- mice, even when administered as monotherapy up to
60 hours after CHIKV infection [28]. In this current study, we engineered the mAb SVIR001,
which was derived from the parent mAb 4N12, and characterized its therapeutic potential.
SVIR001 was as effective in neutralizing CHIKV as the parent 4N12, and therapeutic adminis-
tration of SVIR001 reduced viral burden in joint tissues of wild-type (WT) immunocompetent
mice. In rhesus macaques, SVIR001 treatment at days 1 and 3 after infection eliminated vire-
mia and infectious virus from tissues. SVIR001 reduced CHIKV infection at the inoculating
site and blocked spread to and inflammation within distant tissue sites including joints and
muscles. These results in rhesus macaques suggest the potential for SVIR001 mAb therapy to
reduce CHIKV-associated inflammatory disease in humans.
Methods
Ethics statement
All experiments involving rhesus macaques and mice were performed in compliance with
good animal practices as outlined in local and national animal welfare bodies. Rhesus macaque
studies were performed in the ABSL-3 containment facility at the Oregon National Primate
Research Center (ONPRC). Mouse experiments were performed at Washington University
School of Medicine in an approved ABSL-3 facility (IACUC #20140199). Both facilities are
accredited by the Assessment and Accreditation of Laboratory Animal Care (AAALAC) Inter-
national. All experiments were performed in strict accordance to Institutional Animal Care
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and Use Committee (IACUC) protocols (IACUC #0993). Appropriate procedures were uti-
lized in order to reduce potential distress, pain and discomfort. For example, ketamine (10
mg/kg) was used to sedate the Rhesus macaques during all procedures including routine blood
draws performed by trained veterinary staff. The animals were fed standard monkey chow
with routine food supplements for enrichment. The infected animals were caged with partners
or separately but within visual and auditory contact of other animals in order to promote social
behavior. Animals were euthanized according to the recommendations of the American Veter-
inary Medical Association 2013 Panel on Euthanasia.
Cells and viruses
The infectious clone of CHIKV-LR (CHIKV LR2006 OPY1) was provided generously by Ste-
ven Higgs (Kansas State University, Manhattan, KS). Viral stocks were propagated in BHK21
cells and passaged in C6/36 Aedes albopictus cells. The infectious clone of CHIKV-181/25 was
provided generously by Terence Dermody (University of Pittsburgh, Pittsburgh, PA). Stocks
were propagated in BHK21 cells or Vero cells. CHIKV plaque or focus-forming assays were
performed on Vero cell culture monolayers, as previously described [32, 38]. All cells were cul-
tured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 5–10% fetal bovine
serum (FBS) and penicillin-streptomycin-glutamine. Vero and BHK21 cell monolayer cultures
were grown at 37˚C with 5% CO2, and C6/36 cells were grown at 28˚C with 5% CO2.
Neutralization assays
Neutralization assays with CHIKV were performed as previously described [32]. Approxi-
mately 100 focus-forming units (FFU) of CHIKV-LR were incubated with serial dilutions of
mAbs for 1 h at 37˚C and then plated onto Vero cells. Plates were incubated for 90 minutes at
37˚C and overlaid with a carboxy methylcellulose-containing medium. At 18 h post-infection,
plates were fixed with 1% paraformaldehyde in PBS, and infectious virus was measured by a
FFU assay. Plates were incubated with a detection anti-CHIKV mouse mAb (CHK-11 [32])
diluted in permeabilization solution containing 0.1% saponin and 0.1% bovine serum albumin
followed by an anti-mouse horseradish peroxidase-conjugated secondary antibody. Foci were
visualized using the TrueBlue peroxidase substrate (KPL) and quantified with an ImmunoSpot
5.0.37 microanalyzer (Cellular Technologies Ltd).
Human mAbs
SVIR001 is a recombinant, fully human IgG1 antibody that recognizes the E2 protein of
CHIKV. The complementarity determinant region sequence of the antibody was derived from
the human hybridoma mAb 4N12 [28]. SVIR002 is a recombinant isotype control human
IgG1 mAb directed against chicken lysozyme. Recombinant mammalian cell-expressed
SVIR001 and SVIR002 antibodies were produced at Evitria AG (Wagistrasse 27, 8952 Zurich-
Schlieren, Switzerland). The antibody heavy-chain and light-chain cDNAs were cloned into
Evitria’s evi-5 mammalian gene expression vector. The antibodies were produced by CHO-evi
cells, which are Chinese hamster ovary (CHO) K1 cells adapted to serum-free growth in sus-
pension culture. The seed culture was grown in eviGrow medium, a chemically defined, ani-
mal component-free, serum-free cell culture medium. Transfection and antibody expression
were performed in eviMake at 37˚C and 5% CO2 using eviFect as the transfection reagent. The
cell culture supernatant was harvested by centrifugation eight days after transfection and ster-
ile filtered (0.2 μm). The antibodies were purified by MabSelect SuRe affinity chromatography
using Dulbecco’s PBS as the wash buffer and 0.1 M glycine, pH 3.0–3.5 as the elution buffer.
The purified antibodies were dialyzed against PBS, sterile filtered, and stored at 4˚C. Antibody
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purity was assessed by polyacrylamide gel electrophoresis (Bio-Rad Experion system) under
non-reducing and reducing conditions and determined to be greater than 95% for both
SVIR001 and SVIR002. The percentage of the total antibody present in an aggregated form,
determined by analytical gel filtration chromatography (SEC-HPLC), was less than 0.8% for
SVIR001 and less than 0.1% for SVIR002. Endotoxin was determined with the Charles River
Endosafe-PTS system and found to be less than 1 EU per milligram of antibody.
Generation of SVIR001 escape mutant CHIKV
A CHIKV-181/25 strain SVIR001 escape variant virus was generated by repeated passaging in
the presence of mAb, as previously described [32]. For the first passage, 1.2 x 105 FFU of
CHIKV-181/25 was incubated with 10 μg/ml of SVIR001 for 1 h at 37˚C prior to inoculation
in Vero cells. After 24 hrs, half of the supernatant was removed and incubated with 10 μg/ml
SVIR001 for 1 h, and these complexes were used to inoculate fresh Vero cell monolayer cul-
tures. Following six passages with SVIR001, viral RNA was harvested using QIAamp viral
RNA mini kit (Qiagen) and cDNA was generated with random hexamers and Superscript III
RT (Invitrogen). The cDNA was amplified by PCR and the E2 and E1 genes were sequenced to
identify the genetic change associated with the mAb resistant phenotype. A list of primers used
for sequencing are provided in S1 Table. A deletion of E2 nucleotides 734–739 was identified
and the deletion was engineered into the CHIKV-181/25 and CHIKV-LR infectious clones
using Phusion high fidelity DNA polymerase (New England Biolabs). A list of mutagenesis
primers are provided in S2 Table. The cycling times were 98˚C for 30 sec, 18 cycles of 98˚C for
30 sec, 50˚C for 30 sec, 72˚C 7 min with a final extension at 72˚C for 10 min. The parental plas-
mid was digested with DpnI at 37˚C for 3 h and the mutant plasmid was transformed into
XL-Gold Ultracompetent cells (Agilent). Bacteria were plated onto LB agar supplemented with
100 μg/ml of carbenicillin. Deletion was confirmed by sequencing of the plasmid. WT and
mutant CHIKV were produced after plasmid linearization with NotI (New England Biolabs)
and in vitro transcription with SP6 RNA polymerase (Ambion) following the manufacturer’s
instructions. RNA was electroporated into BHK21 cells using a 2 mm cuvette with 2 pulses (850
V, 25 μF, and infinite resistance). Virus was collected from the supernatant of transfected cells
40 h later. To confirm stability of the mutation, RNA was isolated from virus stocks. cDNA was
produced using Superscript III First Strand Synthesis system (Invitrogen) and amplified using
primers listed in S1 Table or previously described [32] and sequenced directly.
Mouse experiments
CHIKV infections were performed in 4 week-old C57BL/6J WT mice. For the infection stud-
ies, WT mice were inoculated with 103 FFU of CHIKV-LR subcutaneous (s.c.) in the footpad.
At times indicated, the mice were administered 50 or 300 μg anti-CHIKV mAb SVIR001 or
isotype control antibody SVIR002 via an intraperitoneal route. At 3, 5 or 28 dpi, animals were
sacrificed and ankle tissues were homogenized. Ankle viral load was measured by focus form-
ing unit assays on Vero cells or by a TaqMan-based quantitative real time reverse transcription
PCR assay (qRT-PCR, see below).
NHP experiments
Each of twelve male rhesus macaques was inoculated subcutaneously with 107 PFU of CHIKV-
LR diluted in 1 ml of PBS that was distributed over both hands and arms as ten 100 μl injec-
tions as previously described [38]. At 1 and 3 dpi monkeys were infused intravenously with
either control mAb (SVIR002) at 15 mg/kg or anti-CHIKV mAb (SVIR001) at 5 or 15 mg/kg
(see Table 1 for specific animal groupings). The mAbs were diluted with saline into a total of
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20 mls and infused at 1 ml/minute using a medical syringe pump delivery system. Peripheral
blood samples were obtained at 0, 1, 2, 3, 4, 5 and 7 dpi. Whole blood was centrifuged over
lymphocyte separation medium (Corning) for 45 min at 3,000 rpm (1,459 x g) to isolate
peripheral blood mononuclear cells (PBMCs) and plasma. PBMCs were analyzed for lympho-
cyte phenotype and frequency by flow cytometry, and plasma was assessed for viral load by
qRT-PCR and levels of cytokines by a Monkey Magnetic 29-plex Panel for Luminex Platform
Kit (Invitrogen). Animals were euthanized at 7 dpi and complete necropsies were performed.
Representative tissue samples from (joints, muscles, organs, brain, lymph nodes and bone
marrow) were collected and stored in RNAlater, Trizol (RNA isolation), medium (virus isola-
tion), and 10% buffered formalin (microscopic evaluation).
Pharmacokinetic analysis of mAb
Plasma mAb levels were measured by enzyme-linked immunosorbent assay (ELISA). High-
binding polystyrene ELISA plates (Corning) were coated with 100 μl of 107 PFU/ml of CHIKV
181/25 to measure SVIR001 levels or 1 μg/ml of lysozyme (Fisher) in PBS to measure SVIR002
levels. Plates were blocked with 2% milk in 0.05% Tween-PBS followed by incubation with
plasma dilutions in milk/Tween buffer for 2 h. Plates were washed with 0.05% Tween-PBS and
incubated with peroxidase-conjugated anti-human IgG gamma chain (Rockland). Bound anti-
body was detected using the o-phenylenediamine dihydrochloride (OPD) substrate (Life Tech-
nologies), and the plates were read with a Synergy HTX Microplate Reader (BioTek) at 490 nm.
A standard curve was generated using serial dilutions of SVIR001 or SVIR002. Plasma antibody
concentrations were calculated using the standard curve and multiplied by the dilution factor.
qRT-PCR analysis
CHIKV RNA levels were measured using a published qRT-PCR assay [38, 39]. Rhesus macaque
tissues were homogenized in 1 ml of TRIzol reagent plus approximately 250 μl of SiLiBeads, type
S (1.7 to 2.1 mm), using a Precellys 24 homogenizer (Bertin Technologies). Total RNA from tis-
sue samples was prepared using Trizol. Total RNA was prepared from 200 μl of plasma using the
Table 1. CHIKV isolation from tissue homogenates.
mAb Dose
(mg/kg)
Animal Tissue Virus Isolation
SVIR002
(anti-lysozyme control)
15 31559 Spleen, Finger Joints
31055 Finger Joints
31289 Wrist Joints











Three groups of four animals each were treated with control antibody SVIR002 at 15 mg/kg, SVIR001 at 15
mg/kg, or SVIR001 at 5 mg/kg. To isolate CHIKV from the infected joint and muscle tissues an aliquot of
tissue homogenate was incubated in C6/36 cells for four days. Following incubation, infectious virus was
recovered by plaque assay on Vero cells. Only the virus isolation-positive tissues are listed. The limit of
detection was 1 PFU per ml of C6/36 supernatant.
https://doi.org/10.1371/journal.pntd.0005637.t001
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Viral RNA kit (Zymol). The isolated RNA was quantified using a Nanodrop spectrophotometer.
RNA was treated with RNase-free DNase, and then single-stranded cDNA was generated from
1 μg of RNA using random hexamers and Superscript III RT (Invitrogen). Gene amplicons or
viral RNA isolated from infectious virus served as quantification standards (sensitivity, 10 to 100
copies). Quantitative RT-PCR was performed and analyzed using ABI StepOne Plus real-time
PCR system (Applied Biosystems). Relative CHIKV copy numbers of left and right joints and
muscles were averaged for each animal. For the mouse studies, primer and probe sets, as previ-
ously described [40], were used in a one-step reverse transcription (RT)-qPCR assay. Perfused
mouse ankles were homogenized in 1 ml of RLT buffer plus approximately 200 μl of silica beads
using a MagNA Lyser instrument (Roche). RNA was extracted using the RNeasy mini kit (Qia-
gen) following manufacturer’s instructions and eluted in 50 μl of RNase-free water. A one-step
qRT-PCR assay (Applied Biosystems) was performed with 2 μl of RNA using a 7500 Fast real-
time PCR machine (Applied Biosystems). A standard curve was generated with serial dilutions of
RNA extracted from virus stocks to determine CHIKV FFU equivalents. RNA was quantified
using a Nanodrop spectrophotometer and total μg of RNA was determined.
CHIKV isolation from tissues
NHP tissues were homogenized in 1 ml of cell culture medium plus approximately 250 μl of
SiLiBeads using a bead beater (Precellys 24 homogenizer) (Bertin Technologies), and cellular
debris was pelleted by centrifugation (5,000 × g for 2 min). Clarified samples were sterile-fil-
tered (0.45 μm filter), and a 400 μl sample of the clarified lysate was applied to a T25 flask of
C6/36 cells for three days. Supernatant titers from these cultures were determined by limiting
dilution plaque assays on Vero cells. Mouse tissues were titered by focus forming assay. Per-
fused ankles were homogenized in 1 ml of cell culture medium plus approximately 200 μl of
silica beads using the MagNA Lyser. Clarified homogenate was serially diluted and added to a
confluent Vero cells cultured in a 96-well plate. After 2 h, tissue inoculum was removed and
cells were overlaid with a carboxy methylcellulose-containing medium. Cells were fixed 18 h
later and processed as described above.
Phenotypic analysis of PBMCs
PBMCs were analyzed by flow cytometry for cellular differentiation markers as well as Ki67
(marker of active proliferation) or CD169 (activation marker for myeloid lineage cells and nat-
ural killer (NK) cells) as previously described [39]. T cell panel analysis was performed at all
time points, and dendritic cell (DC)/monocyte/macrophage/NK cell panel analysis was per-
formed on PBMCs from 0–5 dpi. For T cell analysis, PBMCs were stained with fluorophore-
conjugated antibodies directed against CD4, CD8β, CD28, CD95, CD127 and Ki67 (Biole-
gend). For DC/monocyte/macrophage/NK analysis, PBMCs were stained with fluorophore-
conjugated antibodies against CD3, CD20, CD14, HLA-DR, CD11c, CD123, CD16, CD8, and
CD169 (Biolegend). The T cell and DC/monocyte/macrophage/NK cell gating strategy is
depicted in S2 Fig and S3 Fig, respectively. Stained samples were read using an LSRII instru-
ment (BD Pharminogen) and the data were analyzed by FlowJo (TreeStar).
CHIKV-specific T cell responses
Monkey gamma interferon (IFNγ) enzyme linked immunospot assays (ELISpotPlus; Mabtech)
were used to quantify CHIKV-specific T cell responses in peripheral blood of infected NHP at 7
dpi. Assays were performed according to the manufacturer’s instructions. Briefly, ELISpot plates
were washed with PBS and blocked with RPMI containing 10% FBS, penicillin/streptomycin, and
glutamine. Approximately, 1.5 x 105 rhesus monkey PBMCs were stimulated with: (1) 1 μl DMSO-
Human monoclonal antibody therapy for chikungunya virus
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005637 June 19, 2017 7 / 25
negative control; (2) overlapping CHIKV peptide pools (10 μg/well; ThermoScientific [39]) of
nsP1, nsP2, nsP3, nsP4, capsid, E3, E2, 6K, or E1; (3) 10 μg of inactivated CHIKV; or (4) 1 μl each
of phorbol 12-myristate 13-acetate (PMA; 40 μM stock) and ionomycin (7 mM stock)-positive
control. The inactivated whole virus was prepared using 3 mM binary ethylenimine (BEI) treat-
ment overnight followed by clarification through a 20% sucrose cushion at 22,000 rpm (68,128 x g)
for 3 hrs; BEI treatment is an established inactivation technique for a number of viruses [41–43].
Successful inactivation of the virus was confirmed by plaque assay. The ELISpot plates were incu-
bated at 37˚C for 18 h and then washed with PBS. Detection of IFNγ was performed by incubating
the plates for 2 h with a biotin-conjugated anti-IFNγ antibody (7-B6-1, Mabtech) diluted in PBS
with 0.5% FCS. Following this incubation, the plates were washed with PBS and then incubated
with streptavidin-alkaline phosphatase in PBS plus 0.5% FBS for 1 h. Plates were washed and then
developed with filtered 5-bromo-4-chloro-3-indolyl-phosphate/nitro blue tetrazolium (BCIP/
NBT) substrate solution; flushing the wells with water stopped this reaction. The plates were air-
dried and scanned using the AID EliSpot Reader Classic (AID). The average spot forming units
per stimulus were calculated and graphed using Graph Pad Prism v6 software.
Serum cytokine assays
Monkey cytokine assays were performed using a Cytokine Monkey Magnetic 29-plex Panel for
Luminex Platform Kit (Invitrogen) according to the the manufacturer’s instructions using a
7-point standard curve. Following a 2 h incubation with monkey plasma, beads were washed
twice and then labeled with biotinylated detector antibody for 1 h. Following additional washes,
beads were incubated with streptavidin conjugated to R-Phycoerythrin for 30 min and washed.
Cytokines were identified and quantified using a Luminex 200 Detection system (Luminex).
Histological analysis
Rhesus macaque joint tissue fixed in 10% buffered formalin was routinely processed, embed-
ded in paraffin, sectioned at 5 microns, and stained with hematoxylin and eosin. Sections of
twelve joints were examined by two pathologists (ADL; LMAC) blinded to group assignment.
A semiquantitative scoring system was developed by assessing inflammation which occurred
in periarticular fat, tendon, connective tissue and/or skeletal muscle. Each joint was scored
individiually and then cumulative socres were calculated for each animal.
Statistical analysis
All statistical analysis was performed in Prism v6 software (GraphPad Software, Inc). EC50 val-
ues were determined by non-linear regression. For plasma viral load and tissue viral burden
from monkeys, data was log-transformed and Dunnett’s multiple comparison test was per-
formed. For mouse viral burden experiments, data was log-transformed, and the Mann-Whit-
ney test was used. For cytokine and chemokine analysis, a Sidak’s multiple comparison test
was used to determine significance.
Results
SVIR001 neutralizes infection in cell culture and in mice
Our previous study demonstrated that combination therapy in NHPs with two mouse mAbs
directed against CHIKV E1 and E2 proteins reduced spread but had limited efficacy at reduc-
ing viral burden in tissues that were infected prior to treatment (i.e., arm and finger joints and
muscle) [38]. Our goal is to develop therapies against CHIKV that could be used during infec-
tion to reduce both viral load in tissues and clinical disease. In the current studies, we modified
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a previously described human mAb (4N12) that demonstrated therapeutic efficacy in immu-
nocompromised mice [28]. We generated a synthetic human IgG1 kappa antibody, SVIR001,
that had identical complementarity determining region amino acid sequences to mAb 4N12.
To confirm that SVIR001 was functionally equivalent to 4N12, we compared their neutraliza-
tion capacities directly. Both mAbs showed similar inhibitory activity to CHIKV-181/25 in
Vero cells (Fig 1A); the concentration required to inhibit 50% of infection (EC50) was similar
(SVIR001 EC50 = 4.1 ng/ml (95%CI 3.2–5.1); 4N12 EC50 = 5.0 ng/ml (95%CI: 4.3–5.9)), with
no statistically significant differences.
4N12 was previously shown to bind E2, and mutagenesis of the arch domain of E2 at posi-
tion D250A prevented 4N12 binding [28]. To determine if the targeting epitope of SVIR001
resembles that of 4N12, CHIKV-181/25 was passaged serially six times in the presence of
10 μg/ml of SVIR001 to obtain a virus that was resistant to SVIR001 inhibition. The escape var-
iant was no longer sensitive to neutralization by SVIR001, whereas infection with the parent
virus was neutralized by SVIR001 (Fig 1B). Sequencing of the gene encoding E2 of the
SVIR001 escape variant virus revealed a six nucleotide deletion in E2 (nucleotides 734–739).
The deletion resulted in substitution of amino acids 245–247 with a single lysine residue (NAE
! K) (S1A Fig). This deletion is adjacent to Asp250, which is important for 4N12 binding to
E2, suggesting that SVIR001 has a similar antigen binding site to 4N12. This six nucleotide
deletion has not been noted to occur naturally, as determined by an alignment of 300 complete
genome sequences of CHIKV (http://www.viprbrc.org). To confirm the escape mutation, the
deletion was engineered into the CHIKV-181/25 and CHIKV-LR infectious clones (E2 del
734–739) (S1B and S1C Fig). The 181/25 and LR E2 del 734–739 viruses were resistant to
SVIR001, whereas the WT viruses were neutralized by SVIR001 (Fig 1C). The LR E2 del 734–
739 and WT viruses however, were neutralized equivalently by a different human anti-CHIKV
mAb (1H12), which bound domain A, B, and arch domain of E2 (Fig 1D) [28]. This result sug-
gested that the six-nucleotide deletion did not cause widespread effects on E2 folding, and that
possible changes in particle-to-plaque forming unit (PFU) ratio between the WT and mutant
virus did not influence neutralization efficiency. These data suggest that SVIR001 and 4N12
bind to the same region of E2 and possess similar neutralizing profiles in vitro.
Our prior studies suggested that the parent mAb 4N12 was effective at mitigating CHIKV-
induced morbidity and mortality in infected Ifnar-/- mice [28]. To assess the in vivo therapeu-
tic efficacy of SVIR001, we used a 4 week-old WT mouse model of CHIKV infection in which
animals are inoculated subcutaneously in the foot and virus replicates preferentially in muscu-
loskeletal tissues [35], as seen in humans. In initial therapeutic studies, we treated CHIKV-
infected WT mice one day post-inoculation (1 dpi) with 50 μg (~3.3 mg/kg) of SVIR001 or
control SVIR002 via an intraperitoneal route and measured infectious viral burden in the ipsi-
lateral and contralateral ankles at 3 dpi. Treatment with SVIR001 resulted in significantly
lower viral titers in both tissues (Fig 1E). We extended the window of treatment and adminis-
tered a single dose of either 50 or 300 μg (3.3 to 20 mg/kg) at 3 dpi and analyzed viral burden
at 5 dpi. SVIR001 treatment significantly reduced viral load in the ipsilateral and contralateral
ankles at 5 dpi (Fig 1F). Moreover, treatment with 300 μg (20 mg/kg) of SVIR001 at 3 and 10
dpi also resulted in lower levels of CHIKV RNA in the contralateral ankle in the chronic
phase, at 28 dpi (Fig 1G). Collectively, the protective activity of SVIR001 in WT mice demon-
strates its feasibility as a post-exposure therapeutic for CHIKV [28].
SVIR001 reduces viral burden in CHIKV-infected rhesus macaques
To further characterize the efficacy of SVIR001, we used a rhesus macaque model of CHIKV
infection [38, 39]. Animals were inoculated subcutaneously with a total of 107 PFU of
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Fig 1. Characterization of neutralization, escape, and therapeutic efficacy of SVIR001 in mice. (A) SVIR001 and parent 4N12 mAbs were evaluated
by neutralization assay in Vero cells. Virus was pre-incubated with indicated concentrations of mAb for 1 h and used to inoculate Vero cells. Data are
reported as the relative infection normalized to a no mAb control. Results are representative of one of three independent experiments performed in duplicate.
(B) The escape variant virus, which was generated by serial passage in the presence of SVIR001, was subjected to neutralization with SVIR001 and
compared to a virus passaged in the absence of SVIR001 (control passaged virus). Results are representative of one of three independent experiments
performed in duplicate. (C-D) Confirmation of SVIR001 escape phenotype with engineered six nucleotide deletion (E2 del 734–739). WT or deletion CHIKV-
181/25 or CHIKV-LR viruses were incubated with indicated mAb for 1 h. Virus-mAb mixture was added to Vero cells. Data was normalized to a no mAb
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CHIKV-LR injected into ten sites on both arms. Following infection, animals displayed ery-
thema and swelling of arm joints (especially the wrist) beginning at 1 to 2 dpi that lasted until
5 dpi. The affected joints were warm to the touch compared to unaffected areas, indicating
active inflammation. Most animals developed a maculopapular rash, and upper extremity
edema that was consistent with previous experiments in NHPs [39, 44]. This effect occurred
irrespective of treatment group and the degree of the rash and swelling appeared different for
each individual monkey. At day 1 and 3 of infection, animals received CHIKV mAb SVIR001
(5 or 15 mg/kg) or isotype control antibody SVIR002 (15 mg/kg) diluted in saline by intrave-
nous infusion (Table 1).
Rhesus macaque infection with CHIKV results in viremia that is detectable at day 1 and
lasts for about 3 to 4 days [38, 39]. To determine the effects of SVIR001 on viremia, blood was
collected on 0, 1, 2, 3, 4, 5, and 7 dpi. The blood drawn on day 1 and 3 after infection occurred
prior to antibody administration. Human antibody levels were measured at all time points by
ELISA; all animals were positive for human anti-CHIKV (SVIR001) or anti-lysozyme antibod-
ies (SVIR002) after the first i.v. treatment (Fig 2A). Antibody levels peaked at 2 and 4 dpi after
the first and second antibody administration, respectively. The SVIR001 and SVIR002 15 mg/
kg dose groups had similar peak plasma human antibody levels at 2 dpi (208 ± 26 μg/ml and
269 ± 88 μg/ml, respectively) and at 4 dpi (333 ± 110 μg/ml and 420 ±114 μg/ml, respectively).
As expected, the group receiving 5 mg/kg SVIR001 had lower plasma human antibody levels at
2 and 4 dpi compared to the 15 mg/kg groups (52 ± 33 μg/ml and 100 ± 68 μg/ml, respectively).
Plasma viral load in the presence of the control antibody SVIR002 was high at 1 dpi and
peaked at 2 dpi (Fig 2B). The levels began to drop at 3 dpi with little residual virus detected at
5 and 7 dpi. Plasma from the animals treated with SVIR001 had high levels of CHIKV at 1 dpi,
and levels dropped to an undetectable range at 2 dpi following treatment and remained unde-
tectable through day 7. Only one SVIR001-treated animal had any detectable virus at 5 dpi,
and the level was near the detection limit of the assay.
In NHP, CHIKV rapidly disseminates (within 2 days) from the initial site of infection, and
is present in many tissues at 7 dpi, including joint and musculoskeletal tissues, lymph nodes,
spleen, heart, lung, and kidney [38]. To demonstrate the efficacy of the mAb treatment on
virus infection and dissemination, animals were euthanized at 7 dpi for tissue viral load analy-
sis. In contrast to control-treated animals, where infectious virus was isolated from the tissue
of at least one joint of all animals, infectious virus was not recovered from any tissue in animals
receiving anti-CHIKV mAb (Table 1). Viral RNA levels in tissues were reduced in the
SVIR001 anti-CHIKV mAb treated animals compared to controls in the arm joint tissues and
muscles (Fig 3A). The reduction of viral RNA in the arms following SVI001 therapy was supe-
rior to previous results with a combination of anti-CHIKV mAbs, which failed to lower viral
loads in the arms of infected macaques [38]. Animals treated with 15 mg/kg SVIR001 had
reduced viral load in finger joints (1.1 x 104 ± 5.8 x 103 vs. 4.8 x 102 ± 1.0 x 102 copies/μg;
P< 0.04) and elbow joints (6.8 x 104 ± 1.1 x 105 vs. 1.5 x 103 ± 2.8 x 103 copies/μg; P< 0.002).
CHIKV infection in the brachial muscle was reduced in both SVIR001 treatment groups (9.7 x
103 ± 1.7 x 104 vs. 45 ± 49 and 69 ± 1.1 x 102 copies/μg, respectively; P< 0.03). Infection also
was reduced at distant musculoskeletal sites by the anti-CHIKV mAb compared to control-
control. Each graph is two independent experiments done in triplicate and the mean ±SD are shown. (E-G) WT mice were inoculated subcutaneously with
103 FFU of CHIKV-LR in the footpad and treated with 50 μg (E-F) or 300 μg (F-G) of anti-CHIKV mAb SVIR001 or control mAb SVIR002 at 1 (E), 3 (F), or 3
and 10 (G) dpi. At 3 (E), 5 (F), or 28 (G) dpi, virus was quantified by infectious focus (E-F) or qRT-PCR (G) assays from the ipsilateral and contralateral ankle
to determine therapeutic efficacy. The median value is shown with the limit of detection indicated by the dotted line. Statistics were calculated on log-
transformed data using the Mann-Whitney test (**, P < 0.01, ***, P < 0.001, ****, P < 0.0001). Each data point represents an individual animal. The data
(E-G) were pooled from 2 independent experiments.
https://doi.org/10.1371/journal.pntd.0005637.g001
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treated animals. Viral load was decreased in the 15 mg/kg SVIR001 treatment group in the
knee (2.0 x 103 ± 2.2 x 103 vs. 1.6 x 102 ±2.8 x 102 copies/μg; P< 0.03) and biceps femoris mus-
cle (1.1 x 103 ± 2.0 x 103 vs. 31 ± 33 copies/μg; P< 0.03) (Fig 3B). We also observed a reduction
of viral load in submandibular lymph nodes, inguinal lymph nodes, mesenteric lymph nodes,
heart, and kidney (Fig 3C). In some tissues there was an SVIR001 concentration-dependent
decrease in viral loads with a greater impact seen with the higher 15 mg/kg dose. This effect
was most evident in the joint tissues of the arms. Similarly, viral loads in the inguinal lymph
nodes were undetected with high dose treatment of SVIR001, which is consistent with the
overall reduction of infection in the legs (6.2 x 103 ± 3.8 x 103 vs. 3.3 ± 6.5 copies/μg;
P< 0.004). No effect of treatment on CHIKV RNA levels was observed in the spleen, as was
seen previously [38]. These results establish the efficacy of SVIR001 therapy in reducing tissue
viral load at the site of infection and spread to distant sites.
SVIR001 inhibited CHIKV-associated inflammation
To evaluate the impact of anti-CHIKV mAb treatment on cellular infiltration into the joints,
we analyzed tissue sections from animals in each treatment group at 7 dpi. Sections consisted
of the soft tissue from the finger, wrist, elbow, toe, ankle, and knee joints bilaterally. The ani-
mals treated with the control mAb SVIR002 had a higher average cumulative score (average
score 10.75) with more inflammation in affected joints and higher numbers of joints affected
within individuals (Table 2, S3 Table). Sections from animals treated with 5 mg/kg (average
score 3.25) and 15 mg/kg (average score 4.75) of SVIR001 had less inflammation within
Fig 2. Plasma antibody levels and viral load following CHIKV mAb therapy. Rhesus macaques were inoculated subcutaneously in both arms
with 1 x 107 PFU of CHIKV LR. On day 1 and 3 after infection, rhesus macaques were administered 5 or 15 mg/kg SVIR001 (human anti-CHIKV
mAb) or 15 mg/kg SVIR002 (human anti-lysozyme mAb), n = 4/group. Blood was collected on 0, 1, 2, 3, 4, 5, and 7 dpi. (A) Human mAb
concentration in the plasma was measured by ELISA with lysozyme or CHIKV virions, and mAb concentration was calculated using a standard
curve. Statistical significance was calculated using Tukey’s multiple comparison test (n = 4; ***, P < 0.0005, **, P < 0.01, *, P < 0.05). (B) Virus
was quantified from plasma by qRT-PCR. Statistically significant differences are reported on the log-transformed data using Dunnett’s multiple
comparison test (n = 4; ****, P < 0.0005).
https://doi.org/10.1371/journal.pntd.0005637.g002
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Fig 3. Tissue viral load following CHIKV mAb therapy. Animals were euthanized at day 7 post-infection,
and viral RNA was isolated from tissues and quantified by qRT-PCR. The viral load in (A) arm joints and
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affected joints and fewer joints affected (Fig 4). Collectively, these results suggest that in rhesus
macaques, SVIR001 therapy reduced viral load in the periphery and thereby prevented or
diminshed acute inflammation in musculoskeletal tissues infected with CHIKV.
To understand the basis for reduced cellular inflammation conferred by SVIR001 treat-
ment, we measured chemokine and cytokine levels in plasma over time on days 0, 1, 2, 3, 5,
and 7 following CHIKV infection using a quantitative 29-plex cytokine magnetic bead assay.
In the control antibody treatment group, there was a significant increase in plasma levels of
IL-1β, G-CSF, IL-6, Eotaxin, MIP-1α, MCP-1, HGF, IFNγ, I-TAC, MIF, IL-1RA, IP-10, and
MIG at 2 dpi (Fig 5 and S3 Fig), which coincides with peak viremia. However, plasma from
the groups that received CHIKV mAb therapy did not show increased levels of these cytokines
and chemokines at 2 dpi. In comparison, plasma levels of FGF-basic, IL-10, IL-12, RANTES,
IL-17, GM-CSF, MIP-1β, IL-15, EGF, IL-5, VEGF, MDC, TNFα, IL-2, IL-4, and IL-8 were
either undetectable or without differences between the treatment groups (S3 Fig). The
decrease of plasma cytokine/chemokine induction at 2 dpi in the SVIR001-treated animals
could account in part for the reduction in joint tissue cell infiltration and inflammation.
We next assessed whether there were differences in levels of activated monocyte/macro-
phages, DCs, or NK cells in blood associated with SVIR001 treatment. PBMCs were stained
with antibodies against the cell surface markers HLA-DR, CD14, CD169, CD11c, CD20, CD3,
CD8, and CD16, and subsets were defined (S2 Fig). In all treatment groups, we observed an
increase in activation of monocyte/macrophages and myeloid DCs as reflected by CD169+
staining peaking at 2–3 dpi followed by a steady decrease, returning to nearly baseline levels
(Fig 6A). However, the number of activated monocytes/macrophages and mDCs was higher
and endured longer in the control mAb-treated (SVIR002) compared to SVIR001-treated ani-
mals (Fig 6A–6C). Similarly, NK cell activation (CD169+ staining) was sustained in the con-
trol-treated compared to anti-CHIKV antibody-treated animals (Fig 6D). These results,
together with decreased plasma levels of inflammatory chemokines and cytokines and
decreased cellular infiltration into the joints of SVIR001 treated animals, suggest that SVIR001
therapy reduced viral burden and consequently inhibited cellular and soluble mediators of
inflammation.
SVIR001 treatment did not diminish anti-CHIKV adaptive immunity
We next determined whether anti-CHIKV mAb therapy altered lymphocyte mobilization and
function. Flow cytometry was used to assess changes in frequency and phenotype of lympho-
cytes in blood during the course of infection. PBMCs were stained with CD4, CD8, CD95, and
CD28 markers to differentiate naïve (NV), central memory (CM), and effector memory (EM)
T cell subsets. Subsequently, the cells were stained with antibodies against Ki67 to determine
the proportion of proliferating T cells. The gating strategies used to define the T cell subsets
and phenotypes are shown in S1 Fig. Over the course of CHIKV infection, we observed an
increase in proliferation of all CD4+ T cells subsets (NV, CM, and EM) with the maximal level
observed at 7 dpi (Fig 7A–7C), as seen previously in NHPs [39]. We did not observe a signifi-
cant difference in T cell phenotype or proliferation status between the SVIR001 and SVIR002
treated animals. Similar to the CD4+ T cell proliferative response, Ki67+CD8+ T cell subsets
from both SVIR001- and SVIR002-treated animals increased throughout infection and the
maximal level was observed at 7 dpi (Fig 7D–7F). Thus, treatment with SVIR001 did not
muscles, (B) leg joints and muscles, and (C) lymphoid tissues, heart and kidney are reported. Statistical
significance was determined on the log-transformed data using Dunnett’s multiple comparison test, and
multiplicity-adjusted P values are reported (n = 4; ** P < 0.005, * P < 0.05).
https://doi.org/10.1371/journal.pntd.0005637.g003
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negatively impact the generation of T cell proliferative responses despite reducing the viral
antigen burden. We also did not observe differences in B cell proliferative responses between
treatment groups (S5 Fig).
The functionality and frequency of the CHIKV-specific T-cell responses in the peripheral
blood was measured using an IFNγ ELISpot. PBMCs isolated at 7 dpi were stimulated with
overlapping peptide pools for the nine different CHIKV proteins [39], inactivated whole virus
(iCHIKV), or PMA/ionomycin as a positive control. CHIKV-reactive T cells were present in
animals from both the control mAb (SVIR002) and anti-CHIKV mAb (SVIR001) treatment
groups (Fig 7G). We did not observe significant differences between the two groups, suggest-
ing that the antibody treatment did not affect the breadth of the CHIKV-specific T cell
response at 7 dpi. These results, along with the T cell proliferation profiles, suggest that
SVIR001 treatment did not negatively impact the generation of anti-CHIKV specific T cell
responses. Thus, an immunotherapeutic mAb against CHIKV can reduce viral loads and pre-
vent CHIKV-induced joint disease without a detectable effect on the induction of antiviral
adaptive immunity, which would prevent disease associated with a second infection.
Discussion
CHIKV is a clinically relevant re-emerging alphavirus that causes chronic polyarthritis and
even death in certain immunocompromised or elderly populations. In the current studies, we
determined the efficacy of SVIR001, a fully human anti-CHIKV immunotherapeutic in mouse
and rhesus macaque models. In WT mice, recombinant antibody substantially reduced levels
of infectious virus from ankle tissues when given at 1 or 3 dpi, and reduced levels of persistent
viral RNA in some joint tissues at 28 dpi. In NHPs, SVIR001 aborted CHIKV viremia, pre-
vented its spread to distal joints and muscle, and reduced viral RNA loads in the hands and
arms, the initial sites of infection. This feature of reducing viral loads in the joints of the arm
Table 2. Histological findings in joint tissues at 7 dpi.
mAb SVIR002 (15 mg/kg) SVIR001 (15 mg/kg) SVIR001 (5 mg/kg)
Right finger 1.5 1 0.25
Left finger 1.5 0.75 0.25
Right wrist 0.5 0.25 0.25
Left wrist 0.75 1.25 1
Right elbow 0.25 0.25 0.75
Left elbow 1.5 0.75 0.25
Right toe 0.5 0 0
Left toe 0.75 0 0
Right ankle 0.5 0 0
Left ankle 0.75 0.25 0
Right knee 1.25 0 0.25
Left knee 1 0.25 0.25
Total score 10.75 4.75 3.25
# joints affected 7.75 3.75 3
Each joint was evaluated for the presence of perivascular infiltrates of lymphocytes, histiocytes and plasma cells in hematoxylin and eosin stained
microscopic sections and assigned a score between 0–3. A score of 0 indicates no evidence of inflammation; 1 indicates few perivascular infiltrates forming
one layer and affecting three vessels or less; 2 indicates perivascular infiltrates forming one to three layers and affecting more than three vessels; 3
indicates perivascular infiltrates forming four or more layers. The average score for each treatment group is reported (n = 4). See S3 Table for the scores for
each animal.
https://doi.org/10.1371/journal.pntd.0005637.t002
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was not observed in a previous study with two mouse anti-CHIKV mAbs (CHK-152 and
CHK-166), suggesting that SVIR001 is more effective at clearing established infections [38].
SVIR001 also reduced CHIKV-induced joint disease, an effect that likely was due to reductions
in viral burden and therefore reduced generalized inflammatory responses. However, this sig-
nature of reduced inflammation did not compromise induction of adaptive B or T cell immu-
nity against the virus. These features make SVIR001 a candidate treatment for humans who
are acutely infected by CHIKV or possibly those suffering from the long-term joint pain
caused by persistent infection.
Acute CHIKV infection in rhesus macaques induces a viremia that lasts for approximately
3 to 4 days, with peak viral titers occurring around 2 to 3 dpi [38, 39, 45, 46]. Virus in plasma
was not detected in animals receiving anti-CHIKV antibody therapy after the first treatment
dose. Anti-CHIKV antibody likely neutralizes virus in the blood rapidly, which reduces dis-
semination to distant sites of infection including the joints and muscles of the legs. Consistent
Fig 4. Histological images of joint-associated tissue from CHIKV-infected animals at 7 dpi. At 7 dpi, joint-associated tissue from the wrist and
finger of each animal were fixed, paraffin embedded, sectioned, and stained with hematoxylin and eosin. Shown are representative images of stained
sections from joint-associated soft tissue of four animals treated with control antibody SVIR002 or CHIKV mAb SVIR001. In the SVIR002 treated
animals, there was abundant inflammation surrounding multiple vessels. In the SVIR001 treated animals (5 or 15 mg/kg dose), there was limited or no
perivascular inflammation.
https://doi.org/10.1371/journal.pntd.0005637.g004
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with this idea, tissue viral loads at 7 dpi were decreased markedly in animals treated with
SVIR001. The reduction in tissue viral loads included those of the joint and muscle tissue from
the arms, the site of infection, which contrasts with our previous findings with mouse CHK-
152 and CHK-166 [38]. Although further studies are required, the marked improvement of
this mAb therapy compared to our previous mAb combination therapy could be due to
Fig 5. CHIKV mAb therapy reduced plasma cytokines and chemokine activation at 2 dpi. Heat map comparing
average fold-change in plasma cytokine profiles for NHP treated inoculated with CHIKV and treated with control antibody
SVIR002 or CHIKV mAb SVIR001. Clustering was performed using the Broad Institute’s webtool Morpheus. A 29-plex-
cytokine magnetic bead assay was performed on plasma from rhesus macaques isolated at day 0, 1, 2, 3, 5, and 7 post-
infection.
https://doi.org/10.1371/journal.pntd.0005637.g005
Human monoclonal antibody therapy for chikungunya virus
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005637 June 19, 2017 17 / 25
different specific mechanism of neutralization, a greater recognition of E2 on the surface of
infected cells that augments effector-based clearance, or a longer relative half-life in plasma.
CHIKV disease is mediated by active replication in musculoskeletal tissues that promotes
immune cell infiltration and production of inflammatory mediators, which causes synovitis,
tenosynovitis, and bone effacement, and results in severe and acute joint pain [3, 13, 47, 48].
High CHIKV levels in human patients have been associated with increased severity of illness
during acute infection [25, 49], and analogously, higher peak viremia in cynomolgus macaques
was associated with worse outcomes including arthritis, meningoencephalitis, and death [45].
High tissue viral loads correlate with an increase in the duration of long-term arthralgia in
patients [3]. Thus, antiviral therapies that reduce viral loads during the acute phase may limit
joint and muscle disease and mitigate chronic CHIKV disease. Histological analysis of the joint
tissues from the infected monkeys at 7 dpi revealed less severe acute disease in the SVIR001
treated compared to the control-treated animals. This observation included a reduction in the
Fig 6. CHIKV mAb therapy reduced activation of peripheral blood monocytes/macrophages, Myeloid DCs, and NK cells. Total
peripheral blood mononuclear cells from 0, 1, 2, 3, 4 and 5 dpi were stained with antibodies directed against HLA-DR, CD14, CD169, CD11c,
CD20, CD3, CD8, and CD16 to assess changes in the activation of macrophage/monocyte, DC, and NK cell subsets. The percent of
activated, CD169+ (A) monocyte/macrophages, (B) plasmacytoid DCs, (C) myeloid DCs, or (D) NK cells within the population are reported
(n = 4).
https://doi.org/10.1371/journal.pntd.0005637.g006
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Fig 7. CHIKV mAb treatment did not cause significant changes in CD4+ or CD8+ T cell proliferation. Rhesus macaques were inoculated with
CHIKV and treated with control antibody SVIR002 or CHIKV mAb SVIR001. Blood was drawn daily 0–7 dpi, and PBMCs were examined for proliferative
responses of different (A-C) CD4+ and (D-F) CD8+ T cell subsets. T cell subsets were defined in S2 Fig as Naïve (NV), Central Memory (CM), and
Effector Memory (EM). The Ki67+ proliferative status was plotted as a percentage of the total population. (G) IFNγ ELISpot analysis was performed on
PBMCs from rhesus macaques at 7 dpi. PBMCs from animals treated with SVIR001 (5 mg/kg or 15 mg/kg) or SVIR002 (15 mg/kg) were stimulated with
CHIKV peptide pools (10 μg/well), inactivated CHIKV (iCHIKV) (10 μg/well), or PMA/Ionomycin as a positive control. DMSO was used as a negative
control to establish the baseline number of IFNγ-producing T cells for each animal. Spots were quantified on an AID ELISpot plate reader (n = 4/group).
https://doi.org/10.1371/journal.pntd.0005637.g007
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number of inflamed joints and a decreased severity of the disease. This finding was supported
by a reduction in cellular infiltration and production of proinflammatory cytokines and chemo-
kines in animals receiving SVIR001 therapy. Several of the cytokines that were diminished in
plasma after SVIR001 treatment are elevated in human plasma during the symptomatic phase
of CHIKV infection, including IFNγ, IP-10, IL-1β, MCP-1, MIG and IL-6 [50–53], with an
increase in IL-1β and IL-6 being linked to more severe disease in humans [53].
SVIR001 and other effective anti-CHIKV therapeutics could serve as treatments for
CHIKV infection. We previously showed the efficacy of 4N12 prophylaxis and acute therapy
in Ifnar-/- mice [28]. We also demonstrated that treatment of mice and monkeys with immu-
notherapeutics during the viremic phase reduces virus dissemination to the distal joints and
tissues [38]. An important, yet unanswered question, is what is the therapeutic window for
antibody treatment against CHIKV? In humans the acute viremic phase following CHIKV
infection lasts 4 to 12 days post symptom onset [14, 54, 55], making this window relatively nar-
row. The clinical utility of an antiviral that works solely by blocking viral dissemination may
be limited due to delays in diagnosis of CHIKV infection during the viremic phase. Further
studies are needed to determine whether SVIR001, alone or in combination with other anti-
bodies or immunomodulatory agents, can reduce musculoskeletal disease, viral burden, or the
transition to persistence when administered at later time points. The addition of a second anti-
body to the cocktail could limit the risk of emergence of resistance [38].
A theoretical concern of immunotherapeutic treatments for CHIKV and other viral infec-
tions is that by quickly eliminating antigen, they may interfere with the development of adap-
tive immunity and render the host susceptible to reinfection. However, we did not observe any
differences in T or B cell proliferation or activation in response to infection when the therapy
was initiated at 1 dpi. Similarly, we did not detect any differences in CHIKV-specific IFNγ-
producing T cell responses at 7 dpi. These observations suggest that SVIR001 did not inhibit
the induction of adaptive immunity and that long-term protection is most likely not compro-
mised by an antiviral therapeutic antibody.
In summary, our results demonstrate that the anti-CHIKV mAb therapeutic SVIR001
reduced viremia and dissemination in infected animals and mitigated inflammation systemi-
cally and locally. Because SVIR001 promotes elimination of CHIKV from infected tissues,
studies are warranted to determine its possible efficacy in preventing or treating viral persis-
tence. Such studies will help to determine the potential clinical utility for prophylaxis or ther-
apy for CHIKV disease.
Supporting information
S1 Fig. Sequence alignment of SVIR001 escape variant viruses. (A) Viral RNA was isolated
from CHIKV-181/25 passaged in the presence of SVIR001, control passaged 181/25, or paren-
tal 181/25. cDNA was produced and sequenced to identify the escape mutation(s). The
sequences were aligned to the CHIKV 181/25 infectious clone using MegAlign (DNAStar).
(B-C) Results of mutagenesis. The six nucleotide deletion (del 734–739) was introduced into
the CHIKV-181/25 (B) or CHIKV-LR (C) infectious clone. WT or deletion mutant viruses
were generated in BHK21 cells. Viral RNA was isolated from stocks, cDNA was produced, and
sequenced to confirm mutation. The sequences were aligned to the CHIKV 181/25 infectious
clone (B) or CHIKV strain LR2006_OPY1 (accession number DQ443544) (C) using MegAlign
(DNAStar). Deletion is highlighted in yellow.
(TIF)
S2 Fig. T cell gating strategy. PBMCs were stained for surface levels of CD4, CD8β, CD95,
CD28, CD127 and for intracellular levels of Ki67. The lymphocyte subset was identified and CD4+
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and CD8+ T subsets are shown (top panel). Within the CD4+ and CD8+ T cell subsets, the naïve
(CD28+CD95-), central memory (CD28+CD95+), and effector memory (CD28-CD95+) subsets are
indicated. The percentage of proliferating (Ki67+) T cells within each subset was calculated.
(TIF)
S3 Fig. Gating strategy for NK cells, macrophages, and DCs. PBMCs were stained with
HLA-DR, CD14, CD11c, CD123, CD20, CD3, CD8, CD16, and CD169 to differentiate mono-
cyte/macrophages, DCs, and NK cells using the following gating strategy: monocyte/macro-
phages (CD3-CD20-CD14+HLA-DR+), plasmacytoid DCs
(CD3-CD20-CD14-HLA-DR+CD123+), myeloid DCs (CD3-CD20-CD14-HLA-DR+CD11c+),
other DCs (CD3-CD20-CD14-HLA-DR+CD123-CD11c-), and NK cells
(CD3-CD20-CD8+CD16+). The percentage of activated cells (CD169+) within each subset was
calculated. The gating strategy and definition of the different cellular subsets are shown.
(TIF)
S4 Fig. Plasma cytokines and chemokine analysis. Cytokine analysis from 29-plex-cytokine
magnetic bead assay was performed on plasma from animals treated with SVIR001 or control
mAb SVIR002. Cytokine analysis revealed changes in plasma cytokine levels of (A) IL-1β, (B)
G-CSF, (C) IL-6, (D) eotaxin, (E) MIP-1α, (F) MCP-1, (G) HGF, (H) IFNγ, (I) I-TAC, (J)
MIF, (K) IL-1RA, (L) IP-10, and (M) MIG. Differences were analyzed using Sidak’s multiple
comparison tests, and adjusted P values are reported (n = 4; , P< 0.0001, , P< 0.0005,
, P< 0.01, , P< 0.05). Individual animals are graphed. Plasma cytokine levels of (N)
FGF-Basic, (O) IL-12, (P) RANTES, (Q) MIP-1β, (R) IL-15, (S) EGF, (T) MDC, (U) IL-2, and
(V) IL-8 did not demonstrate any significant changes between treatment groups. IL-10, IL-17,
GM-CSF, VEGF, TNFα, and IL-4 remained below the limit of detection and are not shown.
(TIF)
S5 Fig. B cell proliferative responses were not affected by SVIR001 therapy. Total peripheral
blood mononuclear cells were analyzed by flow cytometry for the presence of B cell prolifer-
ative responses following CHIKV infection in control and anti-CHIKV treated NHP. B cells
were stained with antibodies directed against CD3, CD20, CD27, IgD and HLA-DR as well as
Ki67 in order to identify proliferating (Ki67+) cells in naïve B cells, memory B cells and mar-
ginal zone like B cells. The percentage of actively proliferating cells within cell type was calcu-
lated using FlowJo software and the data was graphed in GraphPad Prism v6 software.
(TIF)
S1 Table. Primers used for sequencing and amplifying the E2 and E1 genes of CHIKV-
181/25.
(TIFF)
S2 Table. Oligonucleotide primers for mutagenesis of CHIKV infectious clones.
(TIFF)
S3 Table. Detailed histological findings reported per animal. H&E stained joint sections
were scored as described in Table 2. Additional findings such as the presence of granulocytes
or hemosiderin are indicated but were not used in the calculation of scores.  Granulocytes
(eosinophils and/or neutrophils), # Hemosiderin.
(TIFF)
Acknowledgments
We thank Wendy Price for coordinating necropsies and histopathological services.
Human monoclonal antibody therapy for chikungunya virus
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005637 June 19, 2017 21 / 25
Author Contributions
Conceptualization: MSD JEC KC DNS.
Funding acquisition: JEC MSD DNS.
Investigation: RB JMF NH CNK SSP AL PPS MD LMAC RMD ADL DNS.
Methodology: CC SK ADL MKA KC MM PC JR ER IF GS JEC MSD DNS.
Project administration: KC JEC MSD DNS.
Resources: KC MSD DNS.
Supervision: KC JEC MSD DNS.
Validation: KC JEC MSD DNS.
Visualization: RB JMF NH MSD DNS.
Writing – original draft: RB JMF NH ADL KC JEC MSD DNS.
Writing – review & editing: RB JMF NH CNK SSP AL PPS MD CC SK LMAC RMD ADL
MKA KC MM PC JR ER IF GS JEC MSD DNS.
References
1. Voss JE, Vaney MC, Duquerroy S, Vonrhein C, Girard-Blanc C, Crublet E, et al. Glycoprotein organiza-
tion of Chikungunya virus particles revealed by X-ray crystallography. Nature. 2010; 468(7324):709–12.
https://doi.org/10.1038/nature09555 PMID: 21124458.
2. Schilte C, Staikowsky F, Staikovsky F, Couderc T, Madec Y, Carpentier F, et al. Chikungunya virus-
associated long-term arthralgia: a 36-month prospective longitudinal study. PLoS Negl Trop Dis. 2013;
7(3):e2137. https://doi.org/10.1371/journal.pntd.0002137 PMID: 23556021; PubMed Central PMCID:
PMCPMC3605278.
3. Hoarau JJ, Jaffar Bandjee MC, Krejbich Trotot P, Das T, Li-Pat-Yuen G, Dassa B, et al. Persistent
chronic inflammation and infection by Chikungunya arthritogenic alphavirus in spite of a robust host
immune response. J Immunol. 2010; 184(10):5914–27. https://doi.org/10.4049/jimmunol.0900255
PMID: 20404278
4. Sissoko D, Malvy D, Ezzedine K, Renault P, Moscetti F, Ledrans M, et al. Post-epidemic Chikungunya
disease on Reunion Island: course of rheumatic manifestations and associated factors over a 15-month
period. PLoS Negl Trop Dis. 2009; 3(3):e389. https://doi.org/10.1371/journal.pntd.0000389 PMID:
19274071; PubMed Central PMCID: PMCPMC2647734.
5. Gerardin P, Guernier V, Perrau J, Fianu A, Le Roux K, Grivard P, et al. Estimating Chikungunya preva-
lence in La Reunion Island outbreak by serosurveys: two methods for two critical times of the epidemic.
BMC Infect Dis. 2008; 8:99. https://doi.org/10.1186/1471-2334-8-99 PMID: 18662384; PubMed Central
PMCID: PMC2528011.
6. Sergon K, Yahaya AA, Brown J, Bedja SA, Mlindasse M, Agata N, et al. Seroprevalence of Chikungu-
nya virus infection on Grande Comore Island, union of the Comoros, 2005. Am J Trop Med Hyg. 2007;
76(6):1189–93. PMID: 17556634.
7. Sergon K, Njuguna C, Kalani R, Ofula V, Onyango C, Konongoi LS, et al. Seroprevalence of Chikungu-
nya virus (CHIKV) infection on Lamu Island, Kenya, October 2004. Am J Trop Med Hyg. 2008; 78
(2):333–7. PMID: 18256441.
8. Chikungunya Fever Situation in the Country during 2006 (Prov.): National Vector Borne Disease Control
Programme, Delhi, 2006. Available from: http://www.nvbdcp.gov.in/Chikun-cases.html.
9. Chen R, Puri V, Fedorova N, Lin D, Hari KL, Jain R, et al. Comprehensive Genome Scale Phylogenetic
Study Provides New Insights on the Global Expansion of Chikungunya Virus. J Virol. 2016; 90
(23):10600–11. Epub 2016/11/14. https://doi.org/10.1128/JVI.01166-16 PMID: 27654297; PubMed
Central PMCID: PMCPMC5110187.
10. Leparc-Goffart I, Nougairede A, Cassadou S, Prat C, de Lamballerie X. Chikungunya in the Americas.
Lancet. 2014; 383(9916):514. https://doi.org/10.1016/S0140-6736(14)60185-9 PMID: 24506907.
Human monoclonal antibody therapy for chikungunya virus
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005637 June 19, 2017 22 / 25
11. Chikungunya: Statistics Data: Pan American Health Organization; [cited 2016 November]. Available
from: http://www.paho.org/hq/index.php?option=com_topics&amp;view=readall&amp;cid=5927&amp;
Itemid=40931&amp;lang=en.
12. Robinson MC. An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952–53. I.
Clinical features. Trans R Soc Trop Med Hyg. 1955; 49(1):28–32. PMID: 14373834.
13. Borgherini G, Poubeau P, Staikowsky F, Lory M, Le Moullec N, Becquart JP, et al. Outbreak of chikun-
gunya on Reunion Island: early clinical and laboratory features in 157 adult patients. Clin Infect Dis.
2007; 44(11):1401–7. PMID: 17479933. https://doi.org/10.1086/517537
14. Laurent P, Le Roux K, Grivard P, Bertil G, Naze F, Picard M, et al. Development of a sensitive real-time
reverse transcriptase PCR assay with an internal control to detect and quantify chikungunya virus. Clin
Chem. 2007; 53(8):1408–14. https://doi.org/10.1373/clinchem.2007.086595 PMID: 17586592
15. Economopoulou A, Dominguez M, Helynck B, Sissoko D, Wichmann O, Quenel P, et al. Atypical Chi-
kungunya virus infections: clinical manifestations, mortality and risk factors for severe disease during
the 2005–2006 outbreak on Reunion. Epidemiol Infect. 2009; 137(4):534–41. https://doi.org/10.1017/
S0950268808001167 PMID: 18694529
16. Rajapakse S, Rodrigo C, Rajapakse A. Atypical manifestations of chikungunya infection. Trans R Soc
Trop Med Hyg. 2010; 104(2):89–96. https://doi.org/10.1016/j.trstmh.2009.07.031 PMID: 19716149.
17. Borgherini G, Poubeau P, Jossaume A, Gouix A, Cotte L, Michault A, et al. Persistent arthralgia associ-
ated with chikungunya virus: a study of 88 adult patients on reunion island. Clin Infect Dis. 2008; 47
(4):469–75. PMID: 18611153. https://doi.org/10.1086/590003
18. Ge´rardin P, Fianu A, Malvy D, Mussard C, Boussaïd K, Rollot O, et al. Perceived morbidity and commu-
nity burden after a Chikungunya outbreak: the TELECHIK survey, a population-based cohort study.
BMC Med. 2011; 9:5. https://doi.org/10.1186/1741-7015-9-5 PMID: 21235760; PubMed Central
PMCID: PMCPMC3029216.
19. Ozden S, Huerre M, Riviere JP, Coffey LL, Afonso PV, Mouly V, et al. Human muscle satellite cells as
targets of Chikungunya virus infection. PLoS ONE. 2007; 2(6):e527. PMID: 17565380. https://doi.org/
10.1371/journal.pone.0000527
20. Akahata W, Yang ZY, Andersen H, Sun S, Holdaway HA, Kong WP, et al. A virus-like particle vaccine
for epidemic Chikungunya virus protects nonhuman primates against infection. Nat Med. 2010; 16
(3):334–8. PMID: 20111039. https://doi.org/10.1038/nm.2105
21. Plante K, Wang E, Partidos CD, Weger J, Gorchakov R, Tsetsarkin K, et al. Novel chikungunya vaccine
candidate with an IRES-based attenuation and host range alteration mechanism. PLoS Pathog. 2011; 7
(7):e1002142. https://doi.org/10.1371/journal.ppat.1002142 PMID: 21829348; PubMed Central
PMCID: PMCPMC3145802.
22. Chu H, Das SC, Fuchs JF, Suresh M, Weaver SC, Stinchcomb DT, et al. Deciphering the protective
role of adaptive immunity to CHIKV/IRES a novel candidate vaccine against Chikungunya in the A129
mouse model. Vaccine. 2013; 31(33):3353–60. https://doi.org/10.1016/j.vaccine.2013.05.059 PMID:
23727003; PubMed Central PMCID: PMCPMC3731778.
23. Yoon IK, Alera MT, Lago CB, Tac-An IA, Villa D, Fernandez S, et al. High rate of subclinical chikungu-
nya virus infection and association of neutralizing antibody with protection in a prospective cohort in the
Philippines. PLoS Negl Trop Dis. 2015; 9(5):e0003764. https://doi.org/10.1371/journal.pntd.0003764
PMID: 25951202; PubMed Central PMCID: PMCPMC4423927.
24. Galatas B, Ly S, Duong V, Baisley K, Nguon K, Chan S, et al. Long-Lasting Immune Protection and
Other Epidemiological Findings after Chikungunya Emergence in a Cambodian Rural Community, April
2012. PLoS Negl Trop Dis. 2016; 10(1):e0004281. https://doi.org/10.1371/journal.pntd.0004281 PMID:
26752630; PubMed Central PMCID: PMCPMC4713465.
25. Kam YW, Simarmata D, Chow A, Her Z, Teng TS, Ong EK, et al. Early appearance of neutralizing
immunoglobulin G3 antibodies is associated with chikungunya virus clearance and long-term clinical
protection. J Infect Dis. 2012; 205(7):1147–54. PMID: 22389226. https://doi.org/10.1093/infdis/jis033
26. Kam YW, Lum FM, Teo TH, Lee WW, Simarmata D, Harjanto S, et al. Early neutralizing IgG response
to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein.
EMBO Mol Med. 2012; 4(4):330–43. PMID: 22389221. https://doi.org/10.1002/emmm.201200213
27. Kam YW, Lee WW, Simarmata D, Harjanto S, Teng TS, Tolou H, et al. Longitudinal analysis of the
human antibody response to Chikungunya virus infection: implications for serodiagnosis and vaccine
development. J Virol. 2012; 86(23):13005–15. https://doi.org/10.1128/JVI.01780-12 PMID: 23015702
28. Smith SA, Silva LA, Fox JM, Flyak AI, Kose N, Sapparapu G, et al. Isolation and Characterization of
Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya
Virus. Cell Host Microbe. 2015; 18(1):86–95. https://doi.org/10.1016/j.chom.2015.06.009 PMID:
26159721; PubMed Central PMCID: PMCPMC4501771.
Human monoclonal antibody therapy for chikungunya virus
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005637 June 19, 2017 23 / 25
29. Kam YW, Pok KY, Eng KE, Tan LK, Kaur S, Lee WW, et al. Sero-prevalence and cross-reactivity of chikun-
gunya virus specific anti-E2EP3 antibodies in arbovirus-infected patients. PLoS Negl Trop Dis. 2015; 9(1).
30. Kam YW, Lee WW, Simarmata D, Le Grand R, Tolou H, Merits A, et al. Unique epitopes recognized by
antibodies induced in Chikungunya virus-infected non-human primates: implications for the study of
immunopathology and vaccine development. PLoS One. 2014; 9(4):e95647. https://doi.org/10.1371/
journal.pone.0095647 PMID: 24755730; PubMed Central PMCID: PMCPMC3995782.
31. Couderc T, Khandoudi N, Grandadam M, Visse C, Gangneux N, Bagot S, et al. Prophylaxis and therapy
for Chikungunya virus infection. J Infect Dis. 2009; 200(4):516–23. PMID: 19572805. https://doi.org/10.
1086/600381
32. Pal P, Dowd KA, Brien JD, Edeling MA, Gorlatov S, Johnson S, et al. Development of a highly protective
combination monoclonal antibody therapy against Chikungunya virus. PLoS Pathog. 2013; 9(4):
e1003312. https://doi.org/10.1371/journal.ppat.1003312 PMID: 23637602; PubMed Central PMCID:
PMCPMC3630103.
33. Partidos CD, Weger J, Brewoo J, Seymour R, Borland EM, Ledermann JP, et al. Probing the attenua-
tion and protective efficacy of a candidate chikungunya virus vaccine in mice with compromised inter-
feron (IFN) signaling. Vaccine. 2011; 29(16):3067–73. https://doi.org/10.1016/j.vaccine.2011.01.076
PMID: 21300099; PubMed Central PMCID: PMCPMC3081687.
34. Selvarajah S, Sexton NR, Kahle KM, Fong RH, Mattia KA, Gardner J, et al. A neutralizing monoclonal
antibody targeting the acid-sensitive region in chikungunya virus E2 protects from disease. PLoS Negl
Trop Dis. 2013; 7(9):e2423. https://doi.org/10.1371/journal.pntd.0002423 PMID: 24069479; PubMed
Central PMCID: PMCPMC3772074.
35. Hawman DW, Stoermer KA, Montgomery SA, Pal P, Oko L, Diamond MS, et al. Chronic joint disease
caused by persistent Chikungunya virus infection is controlled by the adaptive immune response. J
Virol. 2013; 87(24):13878–88. https://doi.org/10.1128/JVI.02666-13 PMID: 24131709; PubMed Central
PMCID: PMC3838294.
36. Lum FM, Teo TH, Lee WW, Kam YW, Re´nia L, Ng LF. An essential role of antibodies in the control of
Chikungunya virus infection. J Immunol. 2013; 190(12):6295–302. https://doi.org/10.4049/jimmunol.
1300304 PMID: 23670192; PubMed Central PMCID: PMCPMC3677171.
37. Poo YS, Rudd PA, Gardner J, Wilson JA, Larcher T, Colle MA, et al. Multiple immune factors are
involved in controlling acute and chronic chikungunya virus infection. PLoS Negl Trop Dis. 2014; 8(12):
e3354. https://doi.org/10.1371/journal.pntd.0003354 PMID: 25474568; PubMed Central PMCID:
PMCPMC4256279.
38. Pal P, Fox JM, Hawman DW, Huang YJ, Messaoudi I, Kreklywich C, et al. Chikungunya viruses that
escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoes. J
Virol. 2014; 88(15):8213–26. https://doi.org/10.1128/JVI.01032-14 PMID: 24829346; PubMed Central
PMCID: PMC4135940.
39. Messaoudi I, Vomaske J, Totonchy T, Kreklywich CN, Haberthur K, Springgay L, et al. Chikungunya
virus infection results in higher and persistent viral replication in aged rhesus macaques due to defects
in anti-viral immunity. PLoS Negl Trop Dis. 2013; 7(7):e2343. https://doi.org/10.1371/journal.pntd.
0002343 PMID: 23936572; PubMed Central PMCID: PMC3723534.
40. Bellini R, Medici A, Calzolari M, Bonilauri P, Cavrini F, Sambri V, et al. Impact of Chikungunya virus on
Aedes albopictus females and possibility of vertical transmission using the actors of the 2007 outbreak
in Italy. PLoS One. 2012; 7(2):e28360. https://doi.org/10.1371/journal.pone.0028360 PMID: 22383945;
PubMed Central PMCID: PMCPMC3287980.
41. Larghi OP, Nebel AE. Rabies virus inactivation by binary ethylenimine: new method for inactivated vac-
cine production. J Clin Microbiol. 1980; 11(2):120–2. PMID: 7358836; PubMed Central PMCID:
PMCPMC273335.
42. Habib M, Hussain I, Irshad H, Yang ZZ, Shuai JB, Chen N. Immunogenicity of formaldehyde and binary
ethylenimine inactivated infectious bursal disease virus in broiler chicks. J Zhejiang Univ Sci B. 2006; 7
(8):660–4. https://doi.org/10.1631/jzus.2006.B0660 PMID: 16845721; PubMed Central PMCID:
PMCPMC1533761.
43. Bahnemann HG. Binary ethylenimine as an inactivant for foot-and-mouth disease virus and its applica-
tion for vaccine production. Arch Virol. 1975; 47(1):47–56. PMID: 167679.
44. Chen CI, Clark DC, Pesavento P, Lerche NW, Luciw PA, Reisen WK, et al. Comparative pathogenesis
of epidemic and enzootic Chikungunya viruses in a pregnant Rhesus macaque model. Am J Trop Med
Hyg. 2010; 83(6):1249–58. https://doi.org/10.4269/ajtmh.2010.10-0290 PMID: 21118930; PubMed
Central PMCID: PMC2990040.
45. Labadie K, Larcher T, Joubert C, Mannioui A, Delache B, Brochard P, et al. Chikungunya disease in
nonhuman primates involves long-term viral persistence in macrophages. J Clin Invest. 2010; 120
(3):894–906. PMID: 20179353. https://doi.org/10.1172/JCI40104
Human monoclonal antibody therapy for chikungunya virus
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005637 June 19, 2017 24 / 25
46. Binn LN, Harrison VR, Randall R. Patterns of viremia and antibody observed in rhesus monkeys inocu-
lated with chikungunya and other serologically related group A arboviruses. Am J Trop Med Hyg. 1967;
16(6):782–5. PMID: 4965218.
47. Simon F, Parola P, Grandadam M, Fourcade S, Oliver M, Brouqui P, et al. Chikungunya infection: an
emerging rheumatism among travelers returned from Indian Ocean islands. Report of 47 cases. Medi-
cine. 2007; 86(3):123–37. https://doi.org/10.1097/MD/0b013e31806010a5 PMID: 17505252
48. Manimunda SP, Vijayachari P, Uppoor R, Sugunan AP, Singh SS, Rai SK, et al. Clinical progression of
chikungunya fever during acute and chronic arthritic stages and the changes in joint morphology as
revealed by imaging. Trans R Soc Trop Med Hyg. 2010; 104(6):392–9. https://doi.org/10.1016/j.trstmh.
2010.01.011 PMID: 20171708.
49. Chow A, Her Z, Ong EK, Chen JM, Dimatatac F, Kwek DJ, et al. Persistent arthralgia induced by Chi-
kungunya virus infection is associated with interleukin-6 and granulocyte macrophage colony-stimulat-
ing factor. J Infect Dis. 2011; 203(2):149–57. https://doi.org/10.1093/infdis/jiq042 PMID: 21288813;
PubMed Central PMCID: PMCPMC3071069.
50. Wauquier N, Becquart P, Nkoghe D, Padilla C, Ndjoyi-Mbiguino A, Leroy EM. The acute phase of Chi-
kungunya virus infection in humans is associated with strong innate immunity and T CD8 cell activation.
J Infect Dis. 2011; 204(1):115–23. PMID: 21628665. https://doi.org/10.1093/infdis/jiq006
51. Venugopalan A, Ghorpade RP, Chopra A. Cytokines in acute chikungunya. PLoS One. 2014; 9(10):
e111305. https://doi.org/10.1371/journal.pone.0111305 PMID: 25343623; PubMed Central PMCID:
PMCPMC4208842.
52. Kelvin AA, Banner D, Silvi G, Moro ML, Spataro N, Gaibani P, et al. Inflammatory cytokine expression is
associated with chikungunya virus resolution and symptom severity. PLoS Negl Trop Dis. 2011; 5(8):
e1279. https://doi.org/10.1371/journal.pntd.0001279 PMID: 21858242; PubMed Central PMCID:
PMCPMC3156690.
53. Ng LF, Chow A, Sun YJ, Kwek DJ, Lim PL, Dimatatac F, et al. IL-1beta, IL-6, and RANTES as biomark-
ers of Chikungunya severity. PLoS One. 2009; 4(1):21.
54. Appassakij H, Khuntikij P, Kemapunmanus M, Wutthanarungsan R, Silpapojakul K. Viremic profiles in
asymptomatic and symptomatic chikungunya fever: a blood transfusion threat? Transfusion. 2013; 53
(10 Pt 2):2567–74. https://doi.org/10.1111/j.1537-2995.2012.03960.x PMID: 23176378.
55. Panning M, Grywna K, van Esbroeck M, Emmerich P, Drosten C. Chikungunya fever in travelers return-
ing to Europe from the Indian Ocean region, 2006. Emerg Infect Dis. 2008; 14(3):416–22. https://doi.
org/10.3201/eid1403.070906 PMID: 18325256
Human monoclonal antibody therapy for chikungunya virus
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005637 June 19, 2017 25 / 25
